Hamilton G, Reiner A, Teleky B, Roth E, Kolb R, Spona J, Jakesz R
First Surgical Clinic, University of Vienna, Austria.
J Cancer Res Clin Oncol. 1988;114(2):191-6. doi: 10.1007/BF00417836.
Natural killer (NK) cell activity against K 562 erythroleukemic- and MCF-7 breast carcinoma-derived cells was monitored in short-term (3 h/K 562) and long-term (18 h/MCF-7) chromium release tests for 60 patients with untreated primary breast disease. Target cell lysis was the same for patient groups with benign (n = 13) and malignant (n = 47) breast disease (27% versus 36% mean chromium release; target:effector ratio 40:1 for K 562 and 28% versus 40% for MCF-7 cells). NK activity as defined by short-term lysis of K 562 cells did not correlate with MCF-7 cell lysis in long-term assays for the carcinoma patients. This functional heterogeneity of natural cytotoxic activities of breast cancer patients was confirmed by a different age distribution for K 562 and MCF-7 cell lysis and high levels of MCF-7-directed NK activity in the grade I tumor group (56.2%). Our results indicate that measurement of peripheral blood NK activity against a breast carcinoma-derived cell line (MCF-7) defines a disease-related natural cytotoxic activity which correlates better with prognostic tumor parameters (tumor grading) than NK activity as defined by the lysis of K 562 erythroleukemic cells. NK activity testing against breast carcinoma cell lines should be used to monitor natural cytotoxic activities in breast cancer patients and its modulation by different routes of treatment.
在针对60例未经治疗的原发性乳腺疾病患者进行的短期（3小时/K562）和长期（18小时/MCF-7）铬释放试验中，监测了自然杀伤（NK）细胞对K562红白血病细胞和MCF-7乳腺癌衍生细胞的活性。良性（n = 13）和恶性（n = 47）乳腺疾病患者组的靶细胞裂解情况相同（平均铬释放率分别为27%和36%；K562细胞的靶细胞与效应细胞比例为40:1，MCF-7细胞为28%和40%）。在针对癌症患者的长期试验中，由K562细胞的短期裂解所定义的NK活性与MCF-7细胞裂解无关。K562和MCF-7细胞裂解的年龄分布不同以及I级肿瘤组中高水平的针对MCF-7的NK活性（56.2%）证实了乳腺癌患者自然细胞毒性活性的这种功能异质性。我们的结果表明，测量外周血针对乳腺癌衍生细胞系（MCF-7）的NK活性可定义一种与疾病相关的自然细胞毒性活性，与由K562红白血病细胞裂解所定义的NK活性相比，它与预后肿瘤参数（肿瘤分级）的相关性更好。针对乳腺癌细胞系的NK活性检测应用于监测乳腺癌患者的自然细胞毒性活性及其通过不同治疗途径的调节。
